CDK2/FLT4/PDGFRA-IN-1

CDK2/FLT4/PDGFRA-IN-1 (Compound 4a) is a potent inhibitor of CDK2/cyclin A, FLT4 (VEGFR3) and PDGFRA, with IC50s of 1.672, 0.554, and 0.629 μM, respectively. CDK2/FLT4/PDGFRA-IN-1 exhibits potent antiproliferative effects against cancer cells (lung EBC-1, pancreatic ductal adenocarcinoma AsPC-1, colorectal HT-29 cells) . CDK2/FLT4/PDGFRA-IN-1 can also induce apoptosis in cancer cells[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; CDK; PDGFR; VEGFR

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C1C(NC2=CC=C(OCC3=CN(CC4=CC=CC=C4)N=N3)C=C2)=CC(C5=C1C=CC=C5)=O

Molecular Formula

C26H20N4O3

Molecular Weight

436.46

References & Citations

[1]Mardaneh P, et, al. Design, synthesis and pharmacological evaluation of 1,4-naphthoquinone- 1,2,3-triazole hybrids as new anticancer agents with multi-kinase inhibitory activity. Sci Rep. 2025 Feb 24;15 (1) :6639.